Reinvestment of Retained Earnings in R&D
First written in FY2016. 4 of 6 entries say "Restated". Latest entry: FY2024.
51 other companies' latest entry also says "Restated".
- FY2024RestatedAnnual report
「We will actively expand and enhance research and development investment, including drug discovery research such as AI drug discovery, the introduction of new projects, the advancement of clinical projects and the enhancement of research and development facilities; strategic ICT investment in areas such as DX; and capital investment, including production facilities.」
The company has reaffirmed its policy of reinvesting internal funds in drug discovery, AI drug discovery, DX and ICT, and production facilities, among other areas. - FY2022RaisedAnnual report
「We will actively deploy and expand retained funds for research and development investment, including drug discovery research, milestone payments for projects already licensed in, the introduction of new projects and the enhancement of research and development facilities; strategic ICT investment in DX (digital transformation) and other areas; and capital investment, including production facilities.」
The uses of retained earnings have been expanded beyond research and development investment to include strategic DX and ICT investment and production-facility investment. - FY2019RestatedAnnual report
「We will actively invest retained earnings in research and development of the pharmaceuticals sought by patients while responding to anticipated administrative and institutional changes and the continued advance of globalization.」
The company has reaffirmed its policy of investing retained earnings in research and development of pharmaceuticals sought by patients. - FY2018RestatedAnnual report
「We will actively invest retained earnings in research and development of the pharmaceuticals sought by patients while responding to anticipated administrative and institutional changes and the continued advance of globalization.」
The company has reaffirmed its policy of investing retained earnings in research and development of pharmaceuticals sought by patients. - FY2017RestatedAnnual report
「We will actively invest retained earnings in research and development of the pharmaceuticals sought by patients while responding to anticipated administrative and institutional changes and the continued advance of globalization.」
The company has reaffirmed its policy of reinvesting retained earnings in research and development of pharmaceuticals sought by patients. - FY2016First statedAnnual report
「We will actively invest retained earnings in research and development of the pharmaceuticals sought by patients while responding to anticipated administrative and institutional changes and the continued advance of globalization.」
The company indicated its intention to invest retained earnings in research and development, thereby generating future earnings and distributions to shareholders.